Biomarkers for Early Detection of Ovarian Cancer - Webinar

I plan on joining this webinar on Monday the 3rd. Thank you to Elda Rainey of Research Advocacy Network for sharing this information. 

You are invited to participate in an

EDRN Educational Webinar

February 3, 2014  at 1 pm EST
Biomarkers for Early Detection of Ovarian Cancer

 
Michael J. Birrer, MD, PhD

Principal Investigator, Early Detection Research Network (EDRN)

Director, Gynecologic Oncology Research Program
Massachusetts General Hospital Cancer Center

Registration is not required. To add this meeting to your calendar program (for example Microsoft Outlook), click this link:
https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&ICS=MI&LD=1&RD=2&ST=1&SHA2=AAAAAnW1KR3xn4URJAmA/0EPt2R3cDgZ5DalJ7pa7TJv0ep3&RT=MiMxMQ%3D%3D

-------------------------------------------------------
To join the online meeting on Feb 3^rd at 1 pm EST (Now from mobile devices!)
-------------------------------------------------------
1. Go to https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&PW=NYzE3MGFjN2Y0&RT=MiMxMQ%3D%3D
2. If requested, enter your name and email address.
3. If a password is required, enter the meeting password: Advocates$11
4. Click "Join".
Meeting Number: 732 681 403
Meeting Password: Advocates$11
To view in other time zones or languages, please click the link:
https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&PW=NYzE3MGFjN2Y0&ORT=MiMxMQ%3D%3D

-------------------------------------------------------
To join the audio conference only
-------------------------------------------------------
1. Please call one of the following numbers:
Dial In Number: 1-240-276-6338
2. Follow the instructions that you hear on the phone.
Your Cisco Unified MeetingPlace meeting ID: 732 681 403

-------------------------------------------------------

Dee

Every Day is a Blessing!  

OC is Different Diseases with 5 sub-types: Implications for Biomarkers

Vancouver scientists have studied 21 biomarkers from 500 tissue samples from women with ovarian Cancer from 1984-2000. Complete article can be found here.

Conclusion from the article
"The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma."

Livestrong

Dee
Every Day is a Blessing!